You are here: Introduction > Clinical particulars
 
        PreviousNext
 
Tilmovet 100 g/kg Premix:  Clinical particulars
 
 
Tilmovet 100 g/kg Premix
Tilmovet 100 g/kg Premix
Clinical particulars
Target species
Weaned fattening pigs
Indications for use
Tilmovet Premix is indicated for the treatment of pneumonia in weaned fattening pigs, caused by Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida sensitive to tilmicosin.
Contra-indications
Do not use in animals hypersensitive to tilmicosin and when there is resistance to tilmicosin or cross resistance to other macrolides like tylosin, erythromycin or lincomycin.
Tilmicosin is known to be toxic for horses. Do not allow horses or other equines access to feeds containing tilmicosin.
Special warnings for each target species
If for an individual animal, feed intake is such that the recommended dosage is not realized, medication should be carried out by parenteral treatment.
Special precautions for use
Special precautions for use in animals Cross-resistance between tilmicosin and other macrolide antibiotic has been observed. Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies. Inappropriate use of the product may increase the prevalence of bacteria resistant to tilmicosin and may decrease the effectiveness of treatment with tilmicosin related substances.
Special precautions for the person administering the veterinary medicinal product to animals
Accidental ingestion should be avoided by humans.
The handling of the product in case of known hypersensitivity to macrolide antibiotics must be avoided.
May cause sensitisation by skin contact. May cause skin and eye irritation. Avoid direct skin contact. Wear overalls, safety glasses and impervious gloves when mixing and handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water. In case of accidental ingestion, or if you develop symptoms following exposure such as skin rash, seek medical advice immediately and show the package leaflet or the label to the physician
Swelling of the face, lips or eyes or difficulty with breathing are more serious symptoms and require urgent medical attention.
If the operations involve the risk of exposure to dust, wear either a disposable filter and half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 fitted with a filter to EN143. This warning is particularly relevant to on-farm mixing, where the risk of exposure to dust is likely to be enhanced.
Adverse reactions
Occasionally, feed intake may decrease (including feed refusal) in animals receiving medicated feed. This effect is transient.
Use during pregnancy, lactation or lay
Laboratory studies in rats have not produced any evidence of a teratogenic, foetotoxic/embryotoxic effect of tilmicosin, however, a maternotoxicity was observed at doses that were close to the therapeutic dosage. The product can be used in sows whatever the pregnancy stages The safety of tilmicosin has not been established in boars used for breeding purposes.
Interactions
Do not use simultaneously with other macrolides and lincosamides.
Amounts to be administered and administration route
Mix 16 mg tilmicosin/kg bodyweight, in the feed for a period of 15 days.
In order to calculate the exact amount of premix to be added to the feed, use the following formula to achieve the target dose:
  
Dose rate (mg/kg BWt)
x
Average BWt (kg)
 
kg premix per tonne of feed
=
________________________________
 
  
Average feed intake (kg)
x
Premix strength (g/kg)
 
To ensure thorough dispersion of the product it should first be mixed with a suitable quantity of feed before incorporation into the finished feed. Medicated feed may be pelleted using a pre-conditioning step for 5 minutes at a temperature not exceeding 75°C.
Overdose
Vomiting and cardio-vascular collapse are symptoms of overdosing.
Withdrawal periods
Pig meat and offal: 21days
           
 
        PreviousNext
  Date updated: 17 September 2012